Evidence map›Paper›PMID 36898995›Full record

ReviewTranslational psychiatry2023

HSV-1 cellular model reveals links between aggresome formation and early step of Alzheimer's disease.

Marie Alexandra Albaret, Julien Textoris, Bastien Dalzon, Jérémy Lambert, Morgane Linard, Catherine Helmer, Sabine Hacot, Sandra E Ghayad, Martial Ferréol, Hichem C Mertani and 1 more

Open access · goldFull text readReview
In one paragraph

Review in Translational psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Carbon Quantum Dots Assisted Virus Tracking: From Skin to Brain.Advanced materials (Deerfield Beach, Fla.) · 2026
    Article
  6. Review
  7. Article
  8. HSV-1 as a Potential Driver of Alzheimer's Disease.Pathogens (Basel, Switzerland) · 2025
    Review
  9. Review
  10. Frontiers in immunology · 2025
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Marie Alexandra AlbaretUniv Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008, Lyon, France. marie.albaret@lyon.unicancer.fr.ORCID 0000-0003-3374-5298
Julien TextorisEA7426, Joint Research Unit, bioMerieux-HCL-UCBL1, hôpital Edouard Herriot 5 place d'Arsonval, 69437, Lyon, France.
Bastien DalzonChemistry and Biology of Metals, Univ. Grenoble Alpes, CNRS UMR5249, CEA, IRIG, CBM- ProMIT, 17 Avenue des Martyrs, F-38054 Grenoble Cedex 9, Lyon, France.
Jérémy LambertUniv Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008, Lyon, France.
Morgane LinardUniversity of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR U1219, F- 33000, Bordeaux, France.ORCID 0000-0002-5179-4678
Catherine HelmerUniversity of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR U1219, F- 33000, Bordeaux, France.ORCID 0000-0002-5169-7421
Sabine HacotUniv Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008, Lyon, France.
Sandra E GhayadCenter for CardioVascular and Nutrition Research (C2VN), INSERM 1263, INRAE 1260, Aix-Marseille University, Faculty of Pharmacy, Marseille, France.
Martial FerréolINRAE, Ecoflows, UR RiverLy, BP 32108, 69616, 5 Rue de la Doua, 69100, Villeurbanne, France.
Hichem C MertaniUniv Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008, Lyon, France.
Jean-Jacques DiazUniv Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS UMR5286, Centre Léon Bérard, Cancer Research Center of Lyon, 69008, Lyon, France. jean-jacques.diaz@lyon.unicancer.fr.
Université Claude Bernard Lyon 1 · FRUniversité de Bordeaux · FRCentre National de la Recherche Scientifique · FRInserm · FRInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many studies highlight the potential link between the chronic degenerative Alzheimer's disease and the infection by the herpes simplex virus type-1 (HSV-1). However, the molecular mechanisms making possible this HSV-1-dependent process remain to be understood. Using neuronal cells expressing the wild type form of amyloid precursor protein (APP) infected by HSV-1, we characterized a representative cellular model of the early stage of the sporadic form of the disease and unraveled a molecular mechanism sustaining this HSV-1- Alzheimer's disease interplay. Here, we show that HSV-1 induces caspase-dependent production of the 42 amino-acid long amyloid peptide (Aβ42) oligomers followed by their accumulation in neuronal cells. Aβ42 oligomers and activated caspase 3 (casp3A) concentrate into intracytoplasmic structures observed in Alzheimer's disease neuronal cells called aggresomes. This casp3A accumulation in aggresomes during HSV-1 infection limits the execution of apoptosis until its term, similarly to an abortosis-like event occurring in Alzheimer's disease neuronal cells patients. Indeed, this particular HSV-1 driven cellular context, representative of early stages of the disease, sustains a failed apoptosis mechanism that could explain the chronic amplification of Aβ42 production characteristic of Alzheimer's disease patients. Finally, we show that combination of flurbiprofen, a non-steroidal anti-inflammatory drug (NSAID), with caspase inhibitor reduced drastically HSV-1-induced Aβ42 oligomers production. This provided mechanistic insights supporting the conclusion of clinical trials showing that NSAIDs reduced Alzheimer's disease incidence in early stage of the disease. Therefore, from our study we propose that caspase-dependent production of Aβ42 oligomers together with the abortosis-like event represents a vicious circle in early Alzheimer's disease stages leading to a chronic amplification of Aβ42 oligomers that contributes to the establishment of degenerative disorder like Alzheimer's disease in patients infected by HSV-1. Interestingly this process could be targeted by an association of NSAID with caspase inhibitors.

Indexed as

Alzheimer DiseaseHerpesvirus 1, HumanAmyloid beta-PeptidesAnti-Inflammatory Agents, Non-SteroidalCaspasesHumansNeuronsPeptide FragmentsAmyloid beta-PeptidesAnti-Inflammatory Agents, Non-SteroidalCaspasesPeptide Fragments

Identifiers

PMID36898995
PMCPMC10006237
OpenAlexW4323920955

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read48
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.